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ABSTRACT 
 
The sickle cell gene is pleiotropic in nature. Although it is a single gene mutation, it has multiple 
phenotypic expressions that constitute the complications of sickle cell disease. The frequency 
and severity of these complications vary considerably both latitudinally in patients and 
longitudinally in the same patient over time. Thus, complications that occur in childhood may 
disappear, persist or get worse with age. Dactylitis and stroke, for example, occur mostly in 
childhood, whereas leg ulcers and renal failure typically occur in adults. It is essential that the 
phenotypic manifestations of sickle cell disease be defined accurately so that communication 
among providers and researchers facilitates the implementation of appropriate and cost-effective 
diagnostic and therapeutics modalities. The aim of this review is to define the complications that 
are specific to sickle cell disease based on available evidence in the literature and the experience 
of hematologists in this field. 
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INTRODUCTION 
 
Dictionaries define a definition as “an exact statement or description of the nature, scope, or 
meaning of something.” Having such a statement about the complications of sickle cell disease 
facilitates communication among physicians, investigators, ancillary medical staff, insurers, the 
public, patients and their families. Until recently, however, accepted definitions of the 
complications of sickle cell disease did not exist. This state of affairs made it difficult to 
establish cost-effective diagnostic and therapeutic approaches to these complications. To that 
end, a conservative cautious provider, for example, may confuse acute bronchitis with acute 
chest syndrome (ACS) and treat with exchange blood transfusion unnecessarily. On the other 
hand, some providers may under estimate a serious complication of sickle cell disease and delay 
the institution of aggressive therapeutic modalities as needed. In order to fill this gap, the 
comprehensive sickle cell centers supported by the National Institutes of Health (NIH) published 
definitions of the phenotypic complications of sickle cell disease (1,2). These were based on 
whatever evidence that was available in the literature and the experience of a large number of 
hematologists taking care of patients with sickle cell disease for decades. In that publication each 
complication included its 1) definition, 2) diagnostic criteria, 3) severity index if applicable, 4) 
classification if available, and 5) references. In this presentation I will review the definition of 
those complications that are specific to sickle cell disease with emphasis on those not described 
by my colleagues in this Conference Proceedings. Moreover, I will describe the newly described 
complication of sickle cell anemia, neurocognitive impairment that was not described previously. 
 
Genetic and Epigenetic Factors 
 
The phenotype of a complication depends on genetic and epigenetic factors. Genetic factors 
include the mutation or mutations of the gene in question, pleiotropy of the gene if applicable, 
the presence or absence of gene modifiers (also known as epistatic genes) and co-inheritance of 
related genes. Thus, sickle cell anemia is due to a single mutation in the β-globin gene of the 
hemoglobin (Hb) molecule resulting in the replacement of glutamic acid with valine at position 6 
of the β-globin polypeptide. Hb C-Harlem, (also known as Hb C-Georgetown) on the other hand, 
has two mutations on the same β-globin chain including the same sickle mutation described 
above and another mutation at position 73 of the β-globin chain with aspartic acid replacing 
aspargine (3). The sickle gene, in addition, is pleiotropic, meaning that although it is a single 
gene mutation it has multiple phenotypic effects (4). The co-inheritance of Hb C or β-
thalassemia (β-thal) genes with the sickle cell gene affects the phenotypic expression of this 
combination. A complex network of gene modifiers seems to affect the phenotypic expression of 
the sickle cell complications. The Central African Republic (CAR) β haplotype, for example, 
seems to be associated with more severe sickle cell disease (5). 
 
Epigenetic factors that could affect phenotypic expression include the environment, aging, 
drugs/pharmaceuticals and diet (6). The exact mechanism of action of epigenetic factors at the 
molecular level is not well known. It seems that some drugs may cause methylation or 
demethylation of DNA or modification of histones resulting in activation or deactivation of 
certain genes that could affect the phenotypic expression of the gene in question (6). 
 
COMPLICATIONS OF SICKLE CELL DISEASE 
 
Complications of sickle cell disease include four sets of clinical adverse effects: 1) pain 
syndromes; 2) hemolytic anemia and its sequelae; 3) organ damage/failure, and 4) co-morbid 
conditions (7). In this review I will focus on hemolytic anemia and organ damage as shown in 
Table 1. 
 
Hemolytic Anemia and its Sequelae 
 
Aplastic crisis is transient, total or partial suppression of erythropoiesis characterized by a 
decrease in the Hb level and reticulocyte count, or in the number of red blood cell precursors in 
the bone marrow. The decrease in Hb should be ≥20% from baseline and the absolute 
reticulocyte count should be <50,000 or be disproportionately low with respect to the Hb level 
(8). 
 
Hyperhemolysis 
 
Marked drop in Hb with evidence of increased red blood cell destruction in the absence of other 
identifiable causes such as splenic or hepatic sequestration. The decrease in Hb should be ≥20% 
from baseline and the increase in reticulocyte by 25% or presence of nucleated RBC in the 
peripheral smear. Moreover, there should be evidence of hemolysis [increased lactate 
dehydrogenase (LDH), unconjugated bilirubin, or aspartate aminotransferase (AST)], compared 
with baseline WITHOUT recovery from bone marrow suppression (9). 
 
Acute Splenic Sequestration 
 
Rapid intrasplenic trapping of cellular elements of the blood, which causes a precipitous fall in 
Hb level and is often associated with a relative or absolute thrombocytopenia and hypovolemia. 
The decrease in Hb should be ≥20% from baseline and there should be evidence of increased 
erythropoeisis such as increased reticulocyte count ≥25% and an acutely enlarged spleen (≥2 cm) 
(10). 
 
Functional Asplenia 
 
Absent or markedly decreased splenic function in the absence of a surgical or congenital cause. 
There should be increase in pit count (≥3.5%), or presence of Howell-Jolly bodies or lack of 
radionuclide uptake on liver/spleen scan (11). 
 
Hyperviscosity 
 
Whole blood viscosity is a function of both the number and deformability of erythrocytes, as 
well as of the quantity and nature of plasma proteins. In sickle cell disease, viscosity is 
dominated by Hb S gelation and the presence of dense sickle cells. The hyperviscosity syndrome 
in sickle cell disease (and other hemoglobinopathies) occurs most frequently post-transfusion 
(12). 
 
Transfusional Hemosiderosis 
 
Transfusional hemosiderosis or iron overload refers to an increase in total body iron due to 
multiple blood transfusions of ≥20 units or ≥200 mL/kg of red blood cells and serum ferritin 
level of >1000 ng/mL and transferrin saturation >50% on ≥3 serial determinations in the steady 
state or measurement of abnormally increased iron by liver biopsy, SQUID, magnetic resonance 
imaging (MRI) T2* or Ferriscan (13-15). 
 
Organ Damage/Failure (Neurological Complications) 
 
These include cerebrovascular accidents (strokes), transient ischemic attacks, silent infarcts and 
neurocognitive impairment. 
 
Cerebrovascular accidents include infarctive stroke, hemorrhagic stroke and moyamoya. 
Infarctive stroke is an acute neurological syndrome resulting from impaired cerebral blood flow 
without evidence of hemorrhage lasting more than 24 hours. Hemorrhagic stroke is intracranial 
hemorrhage causing neurologic symptoms and signs. Moyamoya is abnormal vascular network 
(“puff of smoke” appearance) indicative of collateral circulation secondary to stenosis or 
occlusion of large cerebral arteries (16,17). Transient ischemic attack is a brief episode of 
neurologic dysfunction caused by focal brain ischemia, with clinical symptoms typically lasting 
less than 1 hour, and without subsequent evidence of cerebral infarction (16,18). Silent cerebral 
infarcts are changes on MRI of brain consistent with infarction without associated history of 
neurologic symptoms or abnormal neurological exam (16, 19). 
 
Neurocognitive impairment is defined by the presence of abnormal non verbal function assessed 
by the Wechsler Adult Intelligence Scale III Performance IQ Index in adult patients with sickle 
cell anemia who are neurologically asymptomatic. This impairment is most likely secondary to 
cerebral hypoxemia undetectable by standard neuroimaging studies (20,21). 
 
Ophthalmologic Complications 
 
The most important and serious ophthalmologic complications of sickle cell disease include the 
following: proliferative sickle retinopathy which are neovascular fronds that emerge from the 
retinal vasculature at the interface of perfused and non perfused retina in response to vascular 
growth factors produced by ischemic retina. The neovascular tissue is predisposed to hemorrhage 
and vitreoretinal traction forces. Although these pre retinal neovascular formations, which may 
resemble and are called sea fans, are bright red when viable, they appear white when 
autoinfarcted or caused to involute by laser photocoagulation (22). 
 
Retinal detachment: separation of the retina from the choroid and eye wall due to holes in the 
retina and traction on the retina by vitreous bands and condensed preretinal membranes (usually 
as sequelae of proliferative sickle retinopathy). Retinal detachment is the most severe 
complication (Stage V) of proliferative sickle retinopathy (23). 
 
Vitreous hemorrhage: bleeding into the vitreous cavity caused by mechanical stress (from trauma 
or normal vitreous movement) on the delicate neovascular fronds growing from the retina into 
the vitreous chamber. Vitreous hemorrhage is a severe complication of proliferative sickle 
retinopathy (24). 
 
Pulmonary Complications 
 
Acute chest syndrome is an acute illness characterized by fever and/or respiratory symptoms, 
accompanied by a new pulmonary infiltrate on chest X-ray (25,26). Pulmonary hypertension is 
an elevation of pulmonary arterial systolic pressure (PASP) (>25 mmHg at rest or >30 mmHg 
with exercise). Cor pulmonale is a term used to describe those with end-stage pulmonary 
hypertension (27). 
 
Renal Complications 
 
Acute renal failure is characterized by an abrupt decline in renal function resulting in an inability 
to excrete metabolic wastes and maintain proper fluid and electrolyte balance (28,29). Hematuria 
is presence of red blood cells in the urine, due to acute renal papillary necrosis, urinary tract 
infection, and less commonly by glomerulonephritis, obstruction, analgesic toxicity, 
mycobacterial infection, nephrolithiasis, tumor (renal cell carcinoma or medullary cell 
carcinoma), arterio-venous malformations, and vasculitis (30). 
 
Priapism is a painful, persistent, unwanted erection of the penis (31). Proteinuria is any 
glomerular disorder associated with protein loss in the urine greater than 100 mg/m2/day (30). 
 
Chronic renal failure is an irreversible and usually progressive reduction in renal function in 
which both kidneys have been damaged to the extent that they are unable to adequately remove 
the metabolic products from the blood and regulate the body’s electrolyte composition and acid-
base balance. End stage renal disease (ESRD) is the final stage in chronic renal insufficiency 
and, by definition, requires dialysis or renal transplantation to prevent death (32). 
 
Hepatobiliary Complications 
 
Hepatic sequestration is sequestration of red blood cells in hepatic sinusoids, leading to liver 
enlargement and decreased Hb concentration by ≥2 g/dL from baseline with reticulocytosis, 
without other explanation and liver enlargement of ≥3 cm for children and ≥5 cm for adults 
(from previous physical examination) without other explanation (33,34). 
 
Intrahepatic cholestasis is intrahepatic obstruction of bile formation or flow leading to 
hyperbilirubinemia. In sickle cell disease, this syndrome may occur in the context of hepatic 
sequestration with the addition of striking hepatic dysfunction. With marked increase in direct 
bilirubin (>50% of total) compared to baseline and absence of extrahepatic biliary system 
obstruction and absence of evidence of marked accelerated hemolysis (35). 
 
Musculoskeletal/Dermatologic Complications 
 
Dactylitis (hand-foot syndrome) is inflammation caused by ischemia/infarction of bone and/or 
bone marrow of the hands and/or feet, resulting in swelling, redness, and pain in affected areas. 
One of the earliest manifestations of sickle cell disease, dactylitis is seen primarily in children 
from 6 months to 3 years of age, and generally does not occur beyond 5 years of age, due to the 
lack of hematopoietic marrow activity in the hands and feet (36). 
 
Avascular necrosis (AVN) is a condition resulting in dead bone tissue due to an interruption in 
blood supply, most likely as a result of vaso-occlusion. Bones near a joint, especially the hip, are 
primarily affected. Avascular necrosis is also referred to as aseptic necrosis, osteonecrosis, or 
ischemic necrosis of the bone (36,37). 
 
Leg ulcers are ulceration of the skin and underlying tissues of the lower extremities, especially 
the medial or lateral surfaces of the ankles. Trauma, infection, and severe anemia may predispose 
patients to ulcer formation (38,39). 
 
CONCLUSIONS 
 
Having definitions of the complications of sickle cell disease based on available evidence in the 
literature and on the experience of hematologists in the field will improve future communications 
among clinical and basic scientists in the field. It is hoped that these preliminary definitions will 
be revised and refined regularly as on-going research and controlled clinical trials in sickle cell 
disease provide a better quality of evidence than what is available at the present. 
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TABLE 1 Complications of Sickle Cell Disease 
 
Hemolytic Anemia and Its Sequelae Pain Syndromes Complications Due to Organ Damage/Failure 
Aplastic episode 
Hyperhemolysis 
Acute splenic sequestration 
Intrasplenic Hemorrhage 
Transfusion related complications 
$ immune hemolysis 
$ RBC antibody sensitization 
$ transfusional hemosiderosis 
 
Sickle cell pain (acute painful crisis) 
Acute multi-organ failure 
Neuropathic pain 
Iatrogenic pain 
Neurological complications 
Ophthalmological complications 
Pulmonary complications 
Renal/genitourinary complications 
Gastrointestinal/hepatobiliary complications 
Muscular/skeletal/skin complications 
 
